Endocrine applications of the somatostatin analogue octreotide (Sandostatin).
Ezzat
S
S
Division of Endocrinology and Metabolism, Cedars-Sinai Medical Center-UCLA School of Medicine 90048.
Melmed
S
S
D000172:Acromegaly / Q000188:drug therapy / Q000378:metabolism; D000236:Adenoma / Q000188:drug therapy / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000378:metabolism; D004702:Endocrine Glands / Q000378:metabolism*; D013006:Growth Hormone / Q000378:metabolism; D013007:Growth Hormone-Releasing Hormone / Q000378:metabolism; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D015282:Octreotide / Q000009:adverse effects / Q000627:therapeutic use*; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000378:metabolism; D013972:Thyrotropin / Q000378:metabolism
D007334:Insulin-Like Growth Factor I; D013972:Thyrotropin; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone; D015282:Octreotide